Business
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the first quarter ended March 31, 2026 and recent corporate highlights. “We have made significant progress in the early quarters of launch driving high ECP awareness, growing prescriber experience and confidence with VIZZ, and have started to build consumer awareness and engagement through our DTC campaigns as we establish a new market for the treatment of presbyopia,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “VIZZ is delivering the kind of real-world efficacy we believed it could, and the early refill dynamics we are seeing continue to reinforce our confidence in the long-term opportunity. Looking ahead, we are focused on helping ECPs integrate VIZZ seamlessly into their practices, improving the patient path from awareness to activation, and continuing to drive adoption as we build this exciting treatment category.” First Quarter 2026 and Recent Corporate Highlights Commercial Launch Q1 2026 product revenues of $1.7 million on approximately 25,000 paid prescriptions of VIZZ®, a 19% increase over Q4 2025.Approximately 46,000 paid prescriptions filled from launch through Q1 2026 representing approximately 1.2 million daily doses sold.Broad uptake by eye care professionals (“ECPs”), with over 10,000 unique prescribers from launch through Q1 2026, with approximately 60% prescribing multiple times.To support growing demand and broad prescriber base, LENZ is expanding its sales force from 88 to 117 territories, increasing the frequency and reach of ECP engagement. The expanded sales force is expected to be fully deployed by the end of Q2 202...